The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
WCLC 2025 | Comparing the safety profile of Teliso-V with other ADCs in lung cancer
Hidehito Horinouchi, MD, PhD, National Cancer Center Hospital, Tokyo, Japan, discusses the differences in the onset of sensory neuropathy between antibody-drug conjugates (ADCs) with the MMA payload, noting that ADCs with the MMA payload have a faster onset of sensory neuropathy compared to ADCs with telisotuzumab vedotin (Teliso-V). The presence of the antibody and linker in the ADC may contribute to the delayed onset of sensory neuropathy, implying that the Teliso-V payload may have a superiority in this aspect. This interview took place at 2025 World Conference on Lung Cancer (WCLC) in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
We have plenty of ADCs having the MMA at the payload. And when we check the other ADCs, the onset of the sensory neuropathy is likely several weeks later. So it’s three times as much faster than the Teliso-V. So that means there might be some kind of a secret of the ADC, because the ADC having the antibody and also the linker and the payload. Even the payload MMA is similar, but when the linker and also the antibody is good, in that case the sensory neuropathy onset can be delayed so long...
We have plenty of ADCs having the MMA at the payload. And when we check the other ADCs, the onset of the sensory neuropathy is likely several weeks later. So it’s three times as much faster than the Teliso-V. So that means there might be some kind of a secret of the ADC, because the ADC having the antibody and also the linker and the payload. Even the payload MMA is similar, but when the linker and also the antibody is good, in that case the sensory neuropathy onset can be delayed so long. So that might be some kind of superiority of the Teliso-V. And also the antibody, Teliso-V, is shown in this trial.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
